

15th Biennial

Ovarian Cancer Research Symposium

Symposium Co-chairs

Joyce Liu, MD, MPH, *Dana-Farber Cancer Institute*

Nita Maihle, PhD, *University of Mississippi*

Brad Nelson, PhD, *Deeley Research Centre, BC Cancer*

Dmitriy Zamarin, MD, PhD, *Icahn School of Medicine at Mount Sinai*

THURSDAY, SEPTEMBER 19

Badge Pickup

6:00 pm – 8:00 pm Lobby

FRIDAY, SEPTEMBER 20

Breakfast (provided)

7:00 am – 8:00 am Evergreen Ballroom

Badge Pickup

7:00 am – 4:00 pm Foyer outside Ballrooms

Welcoming Remarks

8:00 am – 8:10 am

Washington Ballroom

Not CME-eligible

8:00 am

Welcoming Remarks

Jackie Lang, PhD | Rivkin Center for Ovarian Cancer Research

8:06 am

Moment of Silence

Dmitriy Zamarin, MD, PhD | Icahn School of Medicine at Mount Sinai

Opening Keynote

8:10 am – 9:00 am

Washington Ballroom

CME-eligible

8:10 am **Keynote Introduction**

Brad Nelson, PhD | Deeley Research Centre, BC Cancer

8:15 am **The Battle Wages On: Mechanistically-driven cellular therapies to overcome
Keynote** **immuno-resistance in human ovarian cancer**

Jose Conejo-Garcia, MD, PhD | Duke University School of Medicine

Break

9:00 am – 9:15 am

Patient Advocacy Panel - Research is Care: How patients and researchers can work together to bring the bedside back to the bench

9:15 am – 10:45 am

Washington Ballroom

CME-eligible

Chair *Marion Curtis, PhD | Mayo Clinic (Arizona)*

Co-chair *Rinda Soong, MD, PhD | University of Pittsburgh*

Panelist Presentations

9:00 am Bianca Islam, MD, PhD, MSc | Case Western Reserve University

9:05 am Jackie Smith, RPh | Patient Advocate, OCRA Research Reviewer, CDMRP

9:15 am Alvina Nadeem, P. Eng | Ovarian Cancer Canada

9:25 am Kate Hunt | Minnesota Ovarian Cancer Alliance

9:35 am **Panel discussion and Q&A**

Break

10:45 am – 11:00 am

Session 1: Biology of Ovarian Cancer

11:00 am – 12:00 pm

Washington Ballroom

CME-eligible

Chair *Kate Chiappinelli, PhD | George Washington University*

Co-chair *Liz Christie, PhD | Peter MacCallum Cancer Institute*

15th Biennial Ovarian Cancer Research Symposium

Sept 20-21, 2024 | Seattle, WA

Co-presented by the Rivkin Center and AACR

- 11:00 am** **Heterogeneity of acquired resistance in ovarian cancer**
Invited Liz Christie, PhD | Peter MacCallum Cancer Institute
- 11:30 am** **Assessing spatial inter-tumour heterogeneity and homologous recombination deficiency scores in advanced ovarian HGSC (P1)**
Proffered Paula Cunnea, PhD | Imperial College London
- 11:40 am** **Chemotherapy induced TWEAK-Fn14-NF- κ B signaling promotes integrin α V β 3 expression and survival of cancer stem-like cells (P3)**
Proffered Carrie House, PhD | San Diego State University
- 11:50 am** **Post-treatment ovarian tumor cells show interferon pathway enrichment compared to matched pre-treatment tissues (P5)**
Proffered Nomed Girnius, PhD | Harvard Medical School

Lunch (provided)

12:00 pm – 1:30 pm

Atrium

**Poster presenters for Poster Session #1 set up posters*

Breakout Discussions

12:20 pm – 1:20 pm

Evergreen Ballroom and Seattle Rooms

Not CME-eligible

***Must be signed up for Discussions in advance**

Leaders

Ronny Drapkin and Kenneth Nephew

Sarah Adams and Amanda Fader

Kate Chiappinelli and Rebecca Porter

Fiona Simpkins and Liz Christie

Elizabeth Swisher and Deborah Binder

Discussion

DOD Ovarian Cancer Academy Scholars

DOD Clinical Ovarian Cancer Academy

Building clinical and translational collaborations

Navigating regulatory processes and getting funding for translational research

The patient's voice is important in your lab!

Session 1: Biology of Ovarian Cancer, continued

1:30 pm – 3:10 pm

Washington Ballroom

CME-eligible

- 1:30 pm** **What we've learned about long-term survival with HGSC and how to translate this into better outcomes for everyone**
Invited

Leigh Pearce, PhD, MPH | University of Michigan Rogel Cancer Center

- 2:00 pm**
Proffered **The role of deubiquitinase in ovarian cancer tumorigenesis and plasticity (P7)**
Cecil Han, PhD | Georgetown University School of Medicine
- 2:10 pm**
Proffered **Role of cancer-associated mesothelial cells in the immune microenvironment of ovarian tumors (P9)**
Maeva Chauvin, PhD | Massachusetts General Hospital
- 2:20 pm**
Proffered **Tumoroid model recreates clinically relevant phenotypes of HGSC cells, carcinoma associated fibroblasts, and macrophages (P11)**
Kathleen Burkhard | University of Michigan
- 2:30 pm**
Proffered **3D ovarian cancer models with in situ high resolution imaging: a 3D drug discovery platform (P13)**
Erin George, MD | Moffitt Cancer Center
- 2:40 pm**
Proffered **Novel 3D models of advanced ovarian cancer indicate essential roles for JAK/STAT signaling in mediating drug resistance (P15)**
Esther Rodman | Mayo Clinic
- 2:50 pm**
Proffered **Crosstalk between tumour vasculature and ovarian cancer stem cells: the novel angiocrine role of L1CAM (P17)**
Ugo Cavallaro, PhD | European Institute of Oncology
- 3:00 pm**
Proffered **Unlocking the dynamic response of ovarian cancer cells: The transformative role of fluid shear stress and Mucin15 (P19)**
Geeta Mehta, PhD | University of Michigan

Break
3:10 pm – 3:40 pm

Session 2: Prevention, Early Detection, & Interception

3:40 pm – 4:50 pm
Washington Ballroom
CME-eligible

Chair *Naoko Sasamoto, MD, PhD | Brigham and Women's Hospital & Harvard Medical School*
Co-chair *Karen Lu, MD | Moffitt Cancer Center*

3:40 pm
Invited **Implementing salpingectomy as a prevention option for high risk women**
Karen Lu, MD | Moffitt Cancer Center

4:10 pm
Proffered **Multimodal spatial profiling reveals the emergence of an immune suppressive microenvironment in precursors of HGSOC (P51)**
Tanjina Kader, PhD | Harvard Medical School

- 4:20 pm**
Proffered **Ciliated cells prevent high grade serous cancer by regulating STING-p53 DNA damage response (P53)**
Jose Colina, PhD | University of Michigan
- 4:30 pm**
Proffered **Identifying minimum requirements for transformation of tubal epithelial cells in high-grade serous ovarian carcinoma (P55)**
Daryl Phuong | Cornell University
- 4:40 pm**
Proffered **Modeling the inflammatory response of fallopian tube epithelium driven by cancer cell derived-extracellular vesicles (P57)**
Didi Zha, PhD | University of Illinois at Chicago

Break
4:50 pm – 5:10 pm

Session 2: Prevention, Early Detection, & Interception, continued

5:10 pm – 6:00 pm
Washington Ballroom
CME-eligible

- 5:10 pm**
Proffered **Predicting risk of fatal ovarian cancer using a novel two-stage model (P59)**
Shelley Tworoger, PhD | Oregon Health & Science University
- 5:20 pm**
Proffered **Risk reduction for high grade serous ovarian cancer in people who have undergone opportunistic salpingectomy (P61)**
Gillian Hanley, PhD | University of British Columbia
- 5:30 pm**
Proffered **Diet and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium (P63)**
Penelope Webb, PhD | QIMR Berghofer Medical Research Institute
- 5:40 pm**
Proffered **An exploratory analysis of an EV based OC screening test in longitudinal preclinical samples from women with HGSOC (P65)**
Dawn Mattoon, PhD | Mercy BioAnalytics
- 5:50 pm**
Proffered **Plasma proteomic profiles of preclinical and early-stage high-grade serous ovarian cancer (P67)**
Naoko Sasamoto, PhD, MD | Brigham and Women's Hospital and Harvard Medical School

Poster Session #1 & Reception

6:00 pm – 9:00 pm

Atrium

Not CME-eligible

**Poster presenters for Poster Session #1 take down posters by 9:30 pm*

6:45 pm

Reception Program

Molly O'Connor | Rivkin Center for Ovarian Cancer Research

SATURDAY, SEPTEMBER 21

Breakfast (provided)

7:00 am – 8:00 am Evergreen Ballroom

**Poster presenters for Poster Session #2 set up posters*

Badge Pickup

7:00 am – 10:00 am Foyer outside Ballrooms

Session 3: Health & Healthcare Disparities

8:00 am – 9:00 am

Washington Ballroom

CME-eligible

Chair Sophia George, PhD | University of Miami

Co-chair Jennifer Doherty, PhD | Huntsman Cancer Institute, University of Utah

8:00 am Do molecular features of ovarian cancer contribute to disparities in survival?

Invited Jennifer Doherty, PhD | Huntsman Cancer Institute, University of Utah

8:30 am Things we learn from studying ovarian cancer across the African diaspora

Invited Sophia George, PhD | University of Miami

8:45 am Characterization of germline and somatic mutations in homologous recombination genes in high-grade serous ovarian cancer (P74)

Proffered

Katherine Lawson-Michod, PhD | Huntsman Cancer Institute

Break

9:00 am – 9:20 am

Session 4: Emerging Therapeutics

9:20 am – 10:20 am

Washington Ballroom

CME-eligible

Chair *Dmitriy Zamarin, MD, PhD | Icahn School of Medicine at Mount Sinai*

Co-chair *Fiona Simpkins, MD | University of Pennsylvania*

9:20 am **PARP inhibitor combinations in ovarian cancer ...when and for whom?**

Invited Fiona Simpkins, MD | University of Pennsylvania

9:50 am **PARG inhibitor sensitivity correlates with accumulation of ssDNA gaps in preclinical models of ovarian cancer (P76)**

Proffered

Ramya Ravindranathan, PhD | Dana Farber Cancer Institute

10:00 am **Targeting HDAC3 using gene depletion and PROTACs in CCNE1 amplified ovarian cancer (P78)**

Proffered

Vijayalaxmi Gupta, PhD | Washington University in St. Louis

10:10 am **COP5 inhibition targets nucleotide excision repair and homologous recombination to synergize with platinum chemotherapy (P80)**

Proffered

Mary Mullen, MD | Washington University

Break

10:20 am – 10:40 am

Session 4: Emerging Therapeutics, continued

10:40 am – 11:30 am

Washington Ballroom

CME-eligible

10:40 am **Targeting RNA splicing as a novel therapeutic strategy in ovarian high-grade serous carcinoma (P82)**

Proffered

Anke Nijhuis, PhD | Imperial College London

11:10 am **The effects of NR2F2 inhibition on high grade serous ovarian cancer (P84)**

Proffered

Yang Yang-Hartwich, PhD | Yale University

11:20 am **Unlocking CDON: A promising therapeutic target in ovarian cancer (P86)**

Proffered

Floriana Mulas, PhD | Fox Chase Cancer Center

Poster Session #2 and Lunch (provided)

11:30 am – 1:30 pm

Atrium

Not CME-eligible

**Poster presenters for Poster Session #2 take down posters by 1:30 pm*

12:30 pm **Lunch**

Session 5: Novel Immunotherapies

1:30 pm – 2:40 pm

Washington Ballroom

CME-eligible

Chair *Rebecca Porter, MD, PhD | Dana-Farber Cancer Institute*

Co-chair *Jogender Tushir-Singh, PhD | University of California Davis*

1:30 pm **Tracing the Evolution: Fas & Furious targeted antibody design for ovarian cancer**

Invited

Jogender Tushir-Singh, PhD | University of California Davis

2:00 pm **Modulation of epithelial ovarian cancer anti-tumor immunity by a novel cancer cell-intrinsic stress regulator (P118)**

Proffered

Elaheh S. Hosseini, MSc | Rutgers University

2:10 pm **Ovarian cancer-induced stress governs the aggregation of T cell receptor complexes by modulating membrane trafficking (P120)**

Proffered

Rinkee Kumari, PhD | Rutgers Cancer Institute

2:20 pm **The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site and stroma (P122)**

Proffered

Tullia Bruno, PhD | University of Pittsburgh/UPMC Cancer Center

2:30 pm **Losartan rewires ovarian cancer tumor microenvironment and suppresses IGF-1 to amplify chemo-immunotherapy sensitivity (P124)**

Proffered

Lei Xu, PhD, MD | Harvard Medical School

Break

2:40 pm – 3:10 pm

Session 5: Novel Immunotherapies, continued

3:10 pm – 4:00 pm

Washington Ballroom

CME-eligible

- 3:10 pm** **Harnessing senolytic CAR T cells for high grade serous ovarian cancer (P126)**
Proffered Zeda Zhang, PhD | Memorial Sloan Kettering Cancer Center
- 3:40 pm** **Memory-like CAR NK cells engineered to secrete tumor matrix directed IL12 exhibit potent activity against ovarian cancer (P128)**
Proffered Mubin Tarannum, PhD | Dana Farber Cancer Institute
- 3:50 pm** **Targeting the IL-4 pathway in ovarian cancer enhances response to immunotherapy (P130)**
Proffered Alessia Baccarini, PhD | Icahn School of Medicine at Mount Sinai

Closing Keynote

4:00 pm – 4:50 pm

Washington Ballroom

CME-eligible

- 4:00 pm** **Keynote Introduction**
Joyce Liu, MD, MPH | Dana-Farber Cancer Institute
- 4:05 pm** **Targeting Tumor Associated Antigens: Selection, Sequencing and Strategy**
Keynote Kathleen Moore, MD, MS | Stephenson Cancer Center

Closing Remarks

4:50 pm – 5:00 pm

Washington Ballroom

Not CME-eligible

- 4:50 pm** **Closing Remarks**
Nita Maihle, PhD | University of Mississippi

